[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543828":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":39,"responsibleParty":59,"collaborators":61,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":26,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Western Sydney Local Health District","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stereotactic body radiation therapy","EXPERIMENTAL","SBRT within 6 weeks of randomisation guided by previous electrophysiology studies, electrocardiograms and cardiac imaging.",[13],"Radiation: SBRT",{"label":15,"type":16,"description":17,"interventionNames":18},"Catheter ablation","ACTIVE_COMPARATOR","CA within 6 weeks of randomisation (constituting standard of care for patients with VT and structural heart disease)",[19],"Procedure: CA",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","SBRT","Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"PROCEDURE","CA","CA (endocardial and\u002For epicardial at operator discretion) within 6 weeks of randomization.",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Saurabh Kumar, MBBS | PhD","CONTACT","(02)88908140","+61","saurabh.kumar@health.nsw.gov.au",[40],{"facility":41,"status":42,"city":43,"state":26,"zip":26,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Westmead Hospital","RECRUITING","Westmead","Australia","AU",{"type":47,"coordinates":48},"Point",[49,50],150.98768,-33.80383,{"lat":50,"lon":49},[53,56],{"name":54,"role":35,"phone":55,"phoneExt":26,"email":38},"A\u002FProf Kumar","02 8890 8140",{"name":57,"role":58,"phone":26,"phoneExt":26,"email":26},"Saurabh Kumar","PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":57,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Associate Professor",[62,64],{"name":63,"class":6},"University of Sydney",{"name":65,"class":6},"National Heart Foundation, Australia","100543828","radiotherapy-vs-catheter-ablation-for-ventricular-tachycardia-in-structural-heart-disease-100543828",false,"NCT06360939","Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease","RadioAblate-VT","Inclusion Criteria:\n\n1. Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of\n\n   1. segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI\n   2. myocardial hypertrophy\n   3. myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography)\n2. Recurrent monomorphic VT which can include\n\n   1. at least one episode of VT treated by ICD and\u002For\n   2. sustained VT (lasting \\>30s) and\u002For\n   3. inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS)\n3. PAINESD score of ≥9 points and\u002For at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and\u002For mortality after CA.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Life expectancy \\\u003C 3 months\n3. Catheter ablation deemed futile or with prohibitive risk by cardiac electrophysiologist.\n4. Unwilling or unable to provide consent\n5. Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome)\n6. Contraindications to radiotherapy as deemed by referring physician and\u002For radiation oncologist\n7. Pregnancy or breast feeding","ALL","18 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"NA","The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:\n\n* What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months\n* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).",[83,84,85,86],"Ventricular Tachycardia","Cardiomyopathies","Arrhythmias, Cardiac","Ventricular Arrythmia",[88,89,90,91],"catheter ablation","stereotactic body radiation therapy","non invasive","radioablation","2026-02-15",{"date":94,"type":95},"2026-02-18","ACTUAL",{"date":97,"type":95},"2025-11-03",{"date":99,"type":77},"2027-12-20",{"name":5,"class":6},1]